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Background: The patency of arteriovenous access is important for stable and
effective hemodialysis, and long-term technical survival is best achieved with a
native arteriovenous ﬁstula (AVF). However, maintaining AVF patency remains a
challenge. This study was designed to determine the independent prognostic factors
for AVF patency according to hemodialysis duration.
Methods: The primary study end point was unassisted patency of the AVF, which was
deﬁned as the time from the ﬁrst ﬁstula surgery to the ﬁrst AVF failure. AVF failure was
deﬁned as an event that required percutaneous intervention or surgery to revise or
replace the ﬁstula, which occurred at least 2 months after ﬁstula formation.
Results: We enrolled 478 patients with a mean age of 55.5714.0 years, and mean
duration of dialysis was 2.572.1 years. There were 109 cases (22.8%) of AVF failure. The
factors related to AVF patency differed according to hemodialysis duration. Using a Cox-
adjusted model, we observed a signiﬁcant correlation between the incidence of AVF
failure and diabetes within the initial 12 months of hemodialysis. Uncontrolled
hyperphosphatemia (mean serum phosphorus45.5 mg/dL during hemodialysis) was
associated with patency loss of AVF after 1 year of hemodialysis.
Conclusion: Various factors were associated with the development of patency loss of
AVF as hemodialysis duration differed, and a preventive role of hyperphosphatemia
control in AVF survival needs further clinical study.
Copyright & 2015. The Korean Society of Nephrology. Published by Elsevier. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The survival of arteriovenous ﬁstula (AVF) remains an
important problem for hemodialysis patients, accounting for15. The Korean Society of Nep
.org/licenses/by-nc-nd/4.0/).
rtment of Internal Medi-
ug-dong, Ilsangdong-gu,
).20% of all hospitalizations related to AV access problems in
western countries. After a continuous effort to increase the
placement of autologous AVF in the National Kidney Founda-
tion’s original Dialysis Outcomes Quality Initiative (DOQI), the
prevalence of AVF reached up to 55% in March 2010 [1]. Mean
facility use of ﬁstulas in Japan, however, was already 92% in
2003. This difference in AVF placement rate resulted in higher
AVF survival and primary failure occurred in only 7.6% of
ﬁstulas, and 70% of these were recorded in Japan [2]. The
importance of AVF placement is that once the suitability forhrology. Published by Elsevier. This is an open access article under the
Kidney Res Clin Pract 34 (2015) 41–4642dialysis has been achieved, ﬁstula has a better survival com-
pared with AV grafts. The use of AVF is related with fewer
access complications compared with AV grafts, as well as low
risk of infection, hospitalization, and death compared with AV
grafts and catheters.
The clinical risk factors associated with AV access failure are
advanced age, diabetes mellitus, poor surgical technique,
previous catheter insertion, and history of peripheral vascular
diseases [3,4]. AVF patency is involved with speciﬁc genetic
polymorphism in transforming growth factor β1, methylene
tetrahydrofolate reductase, angiotensin-converting enzyme
and length of heme oxygenase-1 [5–8]. We previously
reported that angiotensin-converting enzyme polymorphism
is associated with AVF survival, and serum phosphorus level is
also a clinical factor related to AVF survival [8]. The genetic
polymorphism is not a correctable factor, while serum phos-
phorus level is possible to be controlled in dialysis patients.
If we can establish the modiﬁable risk factors related to
hemodialysis, there is substantial room for improvement of
AVF survival. Therefore, we explored the modiﬁable risk
factors between loss of AVF patency according to hemodialysis
duration and clinical characteristics of patients.Table 1. Demographic, vascular access and clinical characteristics
of patients (n¼478)
Age (y) 55.5714.0
Sex (M:F) 275:203
Mean dialysis duration (y) 2.572.1
Cause of ESRD (%)
Diabetic nephropathy 250 (52.3)
Hypertension 108 (22.6)
Glomerulonephritis 34 (7.1)
Others 40 (8.4)
Unknown 40 (9.6)
Comorbidity (%)
Diabetes 263 (55.0)
Hypertension 373 (78.0)
Ischemic heart disease 92 (19.2)
Cerebrovascular disease 48 (10.0)
Site of AVF (%)
Left side 426 (89.2)
Right side 52 (10.8)
Location of AVF (%)
Forearm 351 (73.4)
Upper arm 127 (26.6)
Temporary catheter use (%) 183 (38.3)
Medications (%)
Anti-platelet agents 384 (80.5)
Warfarin 11 (2.3)
Statins 147 (30.7)
ACEI or ARB use 324 (67.7)
Data are expressed as mean7standard deviation or count (percentage).
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin recep-
tor blocker; AVF, arteriovenous ﬁstula; ESRD, end-stage renal disease.Methods
Patient population
We enrolled end-stage renal disease (ESRD) patients who
were treated with maintenance hemodialysis in 2010 at ﬁve
university or teaching hospitals (Kyung Hee University Hospi-
tal, Kyung Hee University Hospital at Gangdong, Konkuk
University, Hanyang University Guri Hospital, National Health
Insurance Ilsan Hospital) and whose complete medical records
were available retrospectively. Patients were included if they
met the following criteria: (1) creation of a native AVF as the
ﬁrst vascular access irrespective of temporary catheter use for
hemodialysis; (2) formation of the AVF by similar surgical
methods with end-to-side anastomosis; and (3) treatment
with hemodialysis for 4 h, three times weekly. We excluded
patients based on the following criteria: (1) if they received an
AV graft with synthetic material as the ﬁrst vascular access;
(2) access failure occurred within the ﬁrst 2 months after
ﬁstula surgery; and (3) if the ﬁrst episode of AVF failure was
related to an infectious complication, steal phenomenon or
aneurysm.
Clinical variables
Patients’ medical records were used for compiling clinical
data retrospectively, including age, gender, underlying causes
of ESRD, history of ipsilateral central venous catheter insertion,
and the side (right or left) and location (forearm or upper arm)
of the AVF. The causes of ESRD were categorized as diabetes
mellitus, hypertension, glomerulonephritis, others, or
unknown. Laboratory ﬁndings, such as serum hemoglobin,
serum calcium, phosphate, and intact parathyroid hormone
(PTH) were obtained from the medical records. The mean
laboratory levels were calculated from the time of the initial
AVF occurrence to an AVF event. The primary study end point
was unassisted patency of the AVF, which was deﬁned as the
time from the ﬁrst ﬁstula surgery to the ﬁrst patency loss of
AVF. Patency loss of AVF was deﬁned as an event that requiredpercutaneous intervention or surgery to revise or replace the
ﬁstula, which occurred at least 2 months after ﬁstula forma-
tion. The early event was deﬁned as patency loss of AVF within
1 year of the start of hemodialysis, and the late event was
deﬁned as patency loss of AVF after 1 year of hemodialysis.
Additionally, patients were censored at the time of kidney
transplantation, or if they were transferred to other hospitals,
and death with a functioning AVF. The duration between AVF
operation and HD initiation can be differed depending on the
patient's condition but this difference was not considered in
this study.
Statistical analysis
Continuous variables were expressed as mean7standard
deviation. One-way analysis of variance or the Student t test
was used to compare the continuous variables of the groups.
The categorical variables were expressed as counts and per-
centages and analyzed using the χ2 test. The survival curve for
the unassisted AVF patency was assessed by the Kaplan–Meier
method and compared using the log-rank test. The Cox
proportional hazard regression model that allowed adjust-
ment for various baseline differences (age and sex) was used to
conﬁrm the independent prognostic factors associated with
the patency loss of AVF.Results
Patient characteristics
A total of 478 hemodialysis patients with ESRD were
included in this study. Table 1 shows the demographic fea-
tures, vascular access, and clinical characteristics of all the
Moon et al / Hyperphosphatemia and AVF survival 43study patients. The mean age of the population was 55.5714.0
years. The causes of ESRD were diabetic nephropathy (52.3%),
hypertension (22.6%), glomerulonephritis (7.1%), miscella-
neous (8.4%), and unknown (9.6%). A left-sided AVF was
recorded in 426 (89.2%) patients, and a right-sided AVF was
present in 52 (10.8%) patients. The forearm and upper arm for
the AVF location was noted in 351 (73.4%) and 127 (26.6%)
cases, respectively. A temporary central catheter was replaced
in 183 (38.3%) patients. The mean dialysis duration was
2.572.1 years. The unassisted patency of AVF were 85%, 74%
and 66% at 1 year, 3 years and 5 years since AVF creation,
respectively (Fig. 1). Patency loss was reported in 109 (22.8%)
AVFs during the study period.Clinical characteristics of patients with patency loss of AVF
The patients with patency loss of AVF had a signiﬁcantly
higher prevalence of type 2 diabetes mellitus, mean serum
phosphorus level45.5 mg/dL, and mean calciumphosphorusFigure 1. Kaplan–Meier analysis of AVF patency. AVF, arteriovenous
ﬁstula.
Table 2. Clinical characteristics according to patency loss of AVF
AVF without p
Age 55.5
Sex (M:F) 26
Diabetic nephropathy (%) 23
Temporary catheter use (%) 14
Site of AVF (%)
Left side 33
Right side 3
Location of AVF (%)
Forearm 27
Upper arm 9
Mean serum phosphorus level45.5 mg/dL (%) 9
Mean serum calcium level49.5 mg/dL (%) 3
Mean calcium x phosphorus product455 mg2/dL2(%) 3
Mean iPTH (pg/mL)o150 (%) 20
4300 (%) 5
Data are expressed as mean7standard deviation or count (percentage).
AVF, arteriovenous ﬁstula; iPTH, intact parathyroid hormone.product455 (mg2/dL2, Po0.05; Table 2). To determine the
relationship between strict phosphorus control and AVF survival,
patients were classiﬁed into two groups according to mean serum
phosphorus level above or below 5.5 mg/dL, based on the K-
DOQI-recommended level [9]. No signiﬁcant difference was
observed between age, gender, number of temporary central
catheters used, the site or location of the AVF, mean serum
calcium, and mean intact PTH. There was no signiﬁcant difference
in medication use between the two groups.
Factors associated with unassisted patency of AVF
The unassisted patency of the AVF was signiﬁcantly lower
in diabetic mellitus patients than in nondiabetic patients
(Po0.01, Fig. 2A). The patients with mean serum phosphorus
level45.5 mg/dL also showed lower unassisted patency of AVF
(Po0.05, Fig. 2B). Diabetes mellitus and mean serum phos-
phorus level differed signiﬁcantly according to hemodialysis
duration.
Independent factors for AVF survival according to
hemodialysis duration
Among the 109 cases of patency loss of AVF, 62 occurred
within 1 year of hemodialysis. We explored the risk factors
associated with patency loss of AVF before and after 1 year of
hemodialysis. Table 3 shows the Cox regression model for
association of AVF failure with the selected parameters. In the
early event, the unassisted patency of the AVF was signiﬁcantly
lower in diabetes mellitus than in nondiabetic patients
(Table 3, hazard ratio¼2.37, P¼0.002). In case of the late
event, the group with a mean serum phosphorus level below
5.5 mg/dL had a higher AVF survival rate than the group with a
mean serum phosphorus level above 5.5 mg/dL (Table 3,
hazard ratio¼2.17, P¼0.009).Discussion
Most risk factors for AVF failure have already been deter-
mined at the time of surgery, and there are few studies about
risk factors associated with patency loss of AVF according to
the duration of hemodialysis. The risk factors during contin-
uous hemodialysis, such as vascular calciﬁcation, repeatedatency loss (n¼369) AVF with patency loss (n¼109) P
714.0 53.4714.7 0.35
4:174 58:54 0.07
0 (52.6) 70 (62.5) 0.04
8 (40.1) 35 (32.1) 0.58
2 (90) 96 (88)
7 (10) 13 (12) 0.45
8 (75.3) 85 (78.0) 0.08
1 (24.7) 24 (26.6)
4 (23.4) 35 (31.0) 0.03
1 (5.8) 11 (2.1) 0.25
1 (5.8) 15 (2.8) 0.04
8 (38.8) 66 (12.3) 0.26
2 (9.7) 12 (2.2)
Time (since AVF creation, days) Time (since AVF creation, days)
P < 0.05P < 0.01
Figure 2. Kaplan–Meier analysis of AVF patency. Data according to (A) DM versus non-DM and (B) mean serum phosphorus level. AVF,
arteriovenous ﬁstula; DM, diabetes mellitus.
Table 3. Independent factors prognostic of the AVF survival accord-
ing to the hemodialysis durationn
Factor Early event Late event
Hazard
ratio
P-
value
Hazard
ratio
P-
value
Unadjusted Cox model
Male sex 1.04 0.87 0.57 0.05
Age 1.01 0.46 1.01 0.83
Diabetic mellitus 2.37 0.002 1.19 0.66
Ischemic heart disease 1.12 0.25 1.27 0.27
Mean serum phosphorus
level 4 5.5 mg/dL
1.20 0.71 1.85 0.03
Mean serum calcium
level 4 9.5 mg/dL
1.01 0.99 1.04 0.94
Mean serum Ca x P 4 55 1.10 0.83 1.63 0.33
Mean serum iPTH 4 300 1.04 0.84 1.21 0.21
Multivariate adjusted Cox model†
Diabetic mellitus 2.37 0.002 1.60 0.132
Mean serum phosphorus
level 4 5.5 mg/dL
1.20 0.710 2.17 0.009
n Early event: patency loss of arteriovenous ﬁstula occurred within
1 year of hemodialys initiation; Late event: patency loss of arteriove-
nous ﬁstula occurred after 1 year of hemodialysis initiation.
† Adjusted by sex and age. AVF, arteriovenous ﬁstula; Ca  P, calcium 
phosphorus product (mg2/dL2); iPTH, intact parathyroid hormone (pg/
mL).
Kidney Res Clin Pract 34 (2015) 41–4644puncture, and vascular changes in diabetes mellitus may be
related to the patency loss of AVF. In this study, we demon-
strated that known risk factors of patency loss of AVF were
related to early patency loss of AVF. Uncontrolled hyperpho-
sphatemia, however, was related to late patency loss of AVF.
We analyzed clinical risk factors of primary AVF events
before and after 1 year. Other recent studies also reported that
low intra access blood ﬂow (o500 mL/min), diabetes, older
age, and smoking history are clinical risk factors of primary
AVF event within 6 months [10]. During this study, we
presumed that AVF survival would differ according to dialysis
period. Therefore, various factors which might inﬂuence AVF
survival were explored by 6-month period. We conﬁrmed that
different factors from those of the early stage affected AVF
survival at 1 year after initiation of dialysis. Previous studies
reported diabetic patients are at risk of increased primary AVF
failure and reduced primary patency rate [11,12]. In this study,
diabetes was also an independent risk factor for patency loss of
AVF within 1 year. It was interesting that the role of diabetes as
a risk factor for AVF survival decreased after the initial 1 year.
The Dialysis Outcomes and Practice Patterns Study (DOPPS)
showed the difference in ﬁstula placement between Europe and
the US [13]. Furthermore, both ﬁstula and graft survival were
superior in Europe in the DOPPS analysis adjusted for case-mix
[14,15]. A recent study reported the reasons for these differences
in access selection and survival associated with surgical techni-
que. The probability of AVF failure was signiﬁcantly lower for
vascular access surgeons who placedZ25 ﬁstulae during train-
ing [16]. In general, the creation of an AV access is considered as
low priority for surgeons. For this reason, creation of vascular
access is not a procedure that many surgical residents are trained
to perform, and only a few have sufﬁcient experience to perform
it well. However, surgical technique may inﬂuence AVF survival.
A limitation of this study was that we did not evaluate the
inﬂuence of surgical technique.
Hyperphosphatemia is closely associated with vascular
calciﬁcation. Hyperphosphatemia and an elevated CaP pro-
duct are related to cardiovascular mortality in patients with
chronic kidney disease [9,17,18]. For the dialysis patients,
vascular calciﬁcation is associated with hypercalcemia, hyper-
phosphatemia, elevated CaP product, and ingested oralcalcium [19–21]. Medial artery calciﬁcation in which amor-
phous mineral forms circumferentially along or within one or
more elastic lamellae of the medial layer is more prevalent in
patients with diabetes and chronic kidney disease [22]. Most
studies determining vascular calciﬁcation have been per-
formed in vascular smooth cells, which are the main compo-
nent of the medial arterial layer. Many key regulators of bone
formation and bone structural proteins are expressed in both
calciﬁed medial arterial layers and atherosclerotic plaques.
Sage et al [23] reported that elevated levels of phosphorus in
cultured smooth muscular cells induce expression of osteo-
genic genes, such as bone morphogenetic protein and osteo-
pontin. Hyperphosphatemia is more closely associated with
all-cause and cardiovascular mortality than serum calcium
level and iPTH [24]. It is associated with the fact that increased
Moon et al / Hyperphosphatemia and AVF survival 45serum phosphate or phosphate overload may directly promote
vascular injuries, including vascular calciﬁcation, arterial stiff-
ness, endothelial dysfunction, and left ventricular hypertrophy
[25]. Previous studies indicated that the high mean serum
phosphorus level was associated with worse vascular access
survival [26,27]. These studies reported an association
between risk of vascular access thrombosis and increased
serum phosphorus, CaP product, and PTH levels in hemo-
dialysis patients. Previous studies included both native and
polytetraﬂuoroethylene graft, however, we enrolled only
native AVF to avoid confusion.
A limitation of this study was that we only evaluated the
clinical factors related to AVF survival. Other important factors
such as the status of native vein also may inﬂuence the
patency of AVF.
The present study demonstrated that patency loss of AVF in
478 hemodialysis patients was related to the presence of
diabetes and the causative factor within the ﬁrst year of
hemodialysis. Uncontrolled phosphorus level (mean serum
phosphorus level45.5 mg/dL) was the most important factor
in AVF failure at 1 year after hemodialysis. The different risk
factors were associated with patency loss of AVF according to
the hemodialysis duration, and a preventive role of hyperpho-
sphatemia control for AVF survival needs further study.Conﬂict of interest
There is no conﬂict of interest.
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